People with a magnesium deficiency may be less likely to need medication and have better blood pressure control, according to a study in the journal Nature.
The study also suggests a new drug may be able to slow the progression of the disease and reverse the effects of magnesium depletion.
The discovery is important because magnesium is a key ingredient in many prescription drugs and is considered a protective factor against cardiovascular disease and diabetes.
People with the disease usually get symptoms of it at a young age, which makes them vulnerable to cardiovascular disease.
Researchers have known for years that people with high blood pressure have lower levels of magnesium in their bodies than people without it.
The reason is that people in the magnesium-depleted group have higher levels of blood pressure than people who have normal levels of the mineral.
The new study is the first to demonstrate that magnesium depletion leads to a slower progression of magnesium deficiency.
“The idea that it is the combination of both magnesium and blood pressure that leads to these outcomes is something that is well known and has been known for some time,” said study lead author James Gershon, a professor of medicine at the University of Washington in Seattle.
“We think that this study adds a new dimension to the research and offers a new hope for magnesium patients.”
Magnesium is essential for the health of the brain, the heart, the liver and other body systems.
A deficiency in magnesium is associated with several types of conditions, including Alzheimer’s disease, Parkinson’s disease and certain cancers.
It can be reduced by eating a diet high in magnesium, and the researchers believe the drug could be used to reduce magnesium levels in the brain and heart.
The drug is called levodopa and was approved for use in adults over the age of 50 years.
Researchers believe it may be more effective in lowering blood pressure in people who are magnesium deficient than it is in people with normal blood pressure.
Magnesium plays an important role in the heart and brain because it helps regulate blood flow and blood sugar levels.
The amount of magnesium is increased by eating foods rich in magnesium.
People who are deficient in magnesium tend to have higher blood pressure levels and lower levels on average of other factors, including weight and cholesterol.
Gershons research group has also been working on a magnesium drug for the treatment of diabetes.
The treatment, called levitra, has been shown to reduce the effects that magnesium has on blood sugar and triglycerides, two major risk factors for cardiovascular disease, and improve blood flow in the pancreas.
Magnesia, a medication that reduces the symptoms of magnesium loss, is being tested in people suffering from diabetes and the metabolic syndrome.
“In the past, we had some evidence that people who had high blood magnesium levels did have increased risk for type 2 diabetes and elevated triglycerides,” Gersha said.
“But we didn’t know if that was because of the magnesium loss or if it was a result of other problems with magnesium.”
Magnesa, which is also known as levodosaccharide, works by targeting the enzymes responsible for the breakdown of magnesium, which happens in the liver.
The enzyme, called the coenzymes, is a molecule that helps remove magnesium from the body.
The coenzymatic pathway is disrupted by the disease.
“When magnesium is depleted, the cozymes break down the magnesium,” Ghershon said.
He added that the enzyme activity of people with magnesium deficiency is lower than people with a normal magnesium level.
The investigators found that people on levodopan also have reduced levels of coenzys and increased levels of cholesterol.
“There’s a correlation between increased cholesterol and a decrease in cozymatic activity,” Gertz said.
This is consistent with previous studies, which have shown that magnesium loss leads to reduced blood sugar.
“I’m excited to see that people are taking this medication,” said Richard L. Siegel, a research professor at the Mayo Clinic in Rochester, Minnesota, who was not involved in the study.
“People who are on leviodosacchor have been using it for years and years and now we’re seeing it for people with diabetes and metabolic syndrome.”
Siegel was not part of the new study.
He is also a professor at Stanford University in Palo Alto, California, and has studied the effects on blood pressure of levodosa and its co-drug, carbamazepine.
He said it was surprising that the drug would have a lower risk for cardiovascular problems than levodose.
“If we have to treat people for diabetes, we’re going to have to have a lot more of the drugs for diabetes,” Siegel said.
However, Siegel cautioned that the research did not prove that levodosis and levodoses were the cause of the reduction in blood pressure and that there was a need for further studies.
Magsia, which was approved in 2009, is also being tested to treat some forms